Abera Bioscience

Abera Bioscience Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Abera Bioscience (ABERA.SL) as of Nov 16, 2026 is 0.33. In the previous year, Net Debt to Free Cash Flow Ratio was 0.89 — a change of -63.01% (lower).

Net Debt/FCF

0.33

YoY

-63.01%

Last updated:

Net Debt to Free Cash Flow Ratio of Abera Bioscience is 2020 0.33 . Net Debt to Free Cash Flow Ratio of Abera Bioscience was 2019 0.89 . It decreases by -63.01% lower compared to the previous year.

The Abera Bioscience Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2019
0.89 SEK
Jan 1, 2020
0.33 SEK
The Abera Bioscience Net Debt/FCF history
YEARNet Debt/FCFYoY
0.33-63.01%
0.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB develops pharmaceutical products through research and development, focusing on vaccine candidates using its delivery platform. The company aims to advance these candidates to late pre-clinical or early clinical stages before seeking licensing partners for further development. Its technology targets pneumococci and immunooncology, with operations centered in the Nordic market. The business model relies on securing partnerships for vaccine development rather than direct sales, leveraging its platform to attract collaborators in the medical and microbiological sectors. The company's revenue stream comes from licensing agreements with partners who take over further development and commercialization of the vaccine candidates. Abera Bioscience does not sell products directly but instead generates income through these partnerships, which align with its focus on late pre-clinical and early clinical phases. The Nordic market serves as the primary operational region, where the company collaborates with entities in the medical, molecular, and microbiological fields to advance vaccine research. Abera Bioscience AB's business strategy emphasizes platform-based vaccine development, targeting pneumococci and immunooncology areas. The company seeks to transition its vaccine candidates to partners who can handle later-stage development, ensuring the platform's value is realized through collaborative agreements. This approach allows Abera to focus on R&D while partners manage clinical trials and market entry, creating a sustainable revenue model without direct product sales. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

Net Debt to Free Cash Flow Ratio of Abera Bioscience is 0.33 in 2020.

Net Debt to Free Cash Flow Ratio of Abera Bioscience changed from 0.89 to 0.33, representing a -63.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Abera Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Abera Bioscience

All Key Metrics — Abera Bioscience